Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark. The company focuses on developing innovative therapies primarily for rare endocrine diseases and oncology. Its work centers around the proprietary TransCon® technology platform, designed to improve drug delivery by enhancing efficacy, safety, and convenience for patients.
Ascendis has developed several notable products, including Skytrofa®, a once-weekly human growth hormone treatment for pediatric growth hormone deficiency, approved in both the U.S. and European markets. Another key product is Yorvipath® (palopegteriparatide), a treatment for adult chronic hypoparathyroidism, which has been launched in Germany and Austria with plans for broader expansion across Europe. Additionally, the company is advancing TransCon® CNP (navepegritide), a therapy for achondroplasia currently under regulatory review.
The company is recognized for its focus on addressing unmet medical needs in rare diseases through long-acting therapies that reduce treatment burdens for patients. Ascendis combines scientific innovation with strategic regulatory progress to build a diversified pipeline. Its platform technology allows it to develop sustained-release versions of therapeutics, positioning the company to impact multiple indications with significant patient populations.
Ascendis continues to invest in expanding its product portfolio and advancing late-stage clinical trials. The company aims to secure further regulatory approvals and market its therapies across additional geographies. Its strategic development of novel treatments and commitment to rare disease areas underscore its role as a significant player in biopharmaceutical innovation.